Color Genomics Makes Low-Cost Breast and Ovarian Cancer Genetic Risk Test Available Abroad

Apr 11, 2016

|

Premium

NEW YORK (GenomeWeb) – Color Genomics is expanding its reach beyond the US, offering its $249 breast and ovarian cancer genetic risk test to patients and providers in more than 100 countries, including Canada, the UK, many other European countries, and Australia.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Theranos' Holmes Indicted

A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.

Mixed Reaction

Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.

Already Used

A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.

This Week in PLOS

In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more

Featured White Papers

Discovering Neuronal Cell Types

How to Use CrownBio's Integrated Oncology Portfolio for Target Identification and Mechanism of Action Elucidation

Immuno-Oncology: 3 Strategies for Applying Humanized Models

A Guide to Selecting Your Next Immuno-Oncology Model

Jun

19

Featured Webinar

RNA in situ Hybridization: The Next Generation of Immunohistochemistry?

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun

21

Featured Webinar

Evaluation & Implementation of NGS Liquid Biopsy Assays

This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.

Jun

26

Featured Webinar

The Landscape of Alternative Polyadenylation in the Lung Cancer Transcriptome

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.

Jun

27

Featured Webinar

Clinical Utility of Liquid Biopsy for Targeted TKI Therapy in NSCLC

This webinar will present data from the FLAURA trial and show the clinical utility of liquid biopsy in identifying non-small-cell lung cancer (NSCLC) patients who may benefit from targeted TKI therapies.

Main menu